Intest Res > Volume 20(4); 2022 > Article |
|
Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of Interest
Myung SJ is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.
Author Contribution
Conceptualization: Kim SE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Myung SJ. Data curation: Park YE, Lee YJ. Formal analysis: Choi M. Investigation: Park YE, Lee YJ, Kim SE. Methodology: Park YE, Lee YJ, Kim SE, Choi M. Supervision: Kim SE, Myung SJ. Validation: Choi M, Myung SJ. Visualization: Park YE, Lee YJ. Writing - original draft: Park YE, Lee YJ, Kim SE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC. Writing - review & editing: Park YE, Lee YJ, Kim SE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC. Approval of final manuscript: all authors.
The response scale is a 9-Likert scale, ranging from 1 point (strongly disagree) to 9 points (strongly agree), and the closer to 9, the higher strength of agreement; CV=SD/mean.
IBD, inflammatory bowel disease; COVID-19, coronavirus disease 2019; KASID, Korean Association for the Study of Intestinal Diseases; SD, standard deviation; CV, coefficient of variation; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; 5-ASA, 5-aminosalicylic acid.
Drug | Exposed patients to SARS-CoV-2 or SARS-CoV-2 test positive patients without COVID-19 symptoms | COVID-19 confirmed patient (symptomatic) |
---|---|---|
5-ASA | Maintain. | Maintain. |
Corticosteroids | Use when necessary (e.g., acute exacerbation), but reduce the dose if possible. | Use when necessary (e.g., acute exacerbation), but reduce the dose if possible. |
Do not continuously use prednisolone at 20 mg or more per day. Consider dose reduction as soon as possible. | Do not continuously use prednisolone at 20 mg or more per day. Consider dose reduction as rapidly as possible. | |
Immunomodulators (thiopurine/methotrexate) | Withhold for 10-14 days, and if no symptoms of COVID-19, restart. | Withhold for at least 14 days. Restart at least 3 days after recoverya or negative results on 2 consecutive PCR tests. |
Anti-TNF (infliximab, adalimumab, golimumab) | Withhold for 10-14 days, and if no symptoms of COVID-19, restart. | Withhold for at least 14 days. Restart at least 3 days after recoverya or negative results on 2 consecutive PCR tests. |
Vedolizumab | Withhold for 10-14 days, and if no symptoms of COVID-19, restart. | Withhold for at least 14 days. Restart at least 3 days after recoverya or negative results on 2 consecutive PCR tests. |
Ustekinumab | Withhold for 10-14 days, and if no symptoms of COVID-19, restart. | Withhold for at least 14 days. Restart at least 3 days after recoverya or negative results on 2 consecutive PCR tests. |
Tofacitinib | Withhold for 10-14 days, and if no symptoms of COVID-19, restart. | Withhold for at least 14 days. Restart at least 3 days after recoverya or negative results on 2 consecutive PCR tests. |